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Lactulose is often used to treat hepatic encephalopathy or constipation, and also exhibits
benefits to chronic renal insufficiency due to reduce nitrogen-related products in serum. The
present study investigated the pharmacokinetics of lactulose, its removal rate through
dialysis, and safety by administering lactulose 6.5 g (Lagnos Jelly Divided Pack 16.05 g) orally
to six hemodialysis patients who resided in Taiwan. As a result, the means of maximum
plasma concentrations (Cmax) and Time to reach Cmax (Tmax) were 3090 ± 970 ng/mL and
6.5 ± 2.3 hours, respectively. The mean plasma concentration was 2220 ± 986 ng/mL after
administration for 24 hours. Sequentially, the mean plasma concentration reduced to
307 ± 117 ng/mL after the application of 4-hour dialysis. Area under the plasma concen-
tration-time curve from zero to 24 h post-dose (AUC0e24h) were 56,200 ± 21,300 ng h/mL and
the AUC0e28h was 61,200 ± 23,300 ng h/mL. The rate of lactulose removal by dialysis was
83.6 ± 8.9%. In addition, the multiple doses of lactulose using a simulated model suggested
that no plasma accumulation would be expected while coordinating with dialysis. Good
tolerability was confirmed, while the mild adverse effect of diarrhea was observed in one
case during the study period. No death or serious adverse effect was reported. Based on the
present study, we demonstrated the pharmacokinetic transition with respect to plasma
levels of lactulose in patients with impaired renal excretion treated with hemodialysis.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lactulose is a synthetic disaccharide composed of fructose
and galactose. There are no enzymes that degrade lactulose
into monosaccharides in the human gastrointestinal tract. InHospital, Number 92, Sec
Wu).
inistration, Taiwan. Publis
/licenses/by-nc-nd/4.0/).the human body, most of the lactulose reaches the lower
gastrointestinal tract and converts to organic acids (lactic acid,
acetic acid, etc.) by bacterial decomposition, thereby lowering
the pH [1]. Due to acidification of the intestinal tract, the
number of fully-grown lactic acid bacteria increases, whereastion 2, Zhongshan North Road, Zhongshan District, Taipei City
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In agreement, it was also reported that lactulose has prebiotic-
like effects against inflammatory bowel disease [4]. By
increasing the amount of Hþ in the intestinal tract, the NH3
would preferentially convert to nonabsorbable NH4
þ, thus
lowering the ammonia concentration in blood [5], for which
can treat hepatic encephalopathy or related seizures [6]. It has
also been shown that a laxative effect is induced in the lower
gastrointestinal tract by osmotic regulation.
Due to toxic compounds that are accumulated in patients
with chronic renal failure (CRF) [7], some treatments are able
to assist with the excretion of unwanted wastes from bodies.
In 1971, lactulose therapy was first applied to treat uremic
toxins in patients with CRF [8]. Based on a published study
conducted with healthy men, lactulose was poorly absorbed
and could be found in urinary excretion relative to its oral
amount by only 0.65% [9]. However, given that CRF is usually
altered the pharmacokinetic profile of medicines, it is neces-
sary to understand the plasma transition of lactulose in pa-
tients with impaired renal function and on dialysis.
For this study, our purpose was to investigate the phar-
macokinetics of lactulose including the removal rate of dial-
ysis by administering a single oral dose of lactulose (6.5 g) in
hemodialysis patients.2. Materials and methods
2.1. Drug information
The investigational drug was a jelly containing 6.5-g lactulose
(Lagnos Jelly Divided Pack 16.05 g, Sanwa Kagaku Kenkyusho
Co., Ltd., Nagoya, Japan).
2.2. Study population and design
A total of six hemodialysis patients were proposed to enroll
into the study. This study followed the Taiwan Law of Phar-
maceutical Affairs, Good Clinical Practices, local regulatory
requirements, and was according to the Revised Declaration
of Helsinki [10]. Before screening started, participants were
verified to be fully aware of the purpose, content, and possible
side effects of this study which were described in the
informed consent. Signed informed consent was obtained
from all individual participants enrolled in the study. Ethical
approval for the study was received from Mackay Memorial
Hospital Institutional Review Board, Taipei, Taiwan. Six
Taiwanese patients including two men and four women with
chronic renal failure who required regular hemodialysis 3
times/wk participated in this study. Their mean age was
48.5± 4.9 years (mean± standard deviation) withmeanweight
of 56.4 ± 16.4 kg and a mean body mass index of 22.4 ± 4.3 kg/
m2. All patients had to satisfy inclusion/exclusion criteria
throughout the study. Exclusion criteria were diabetes (the
last 2 glycated hemoglobin measurements >8% with at least 1
measure within 3 months of enrollment), anemia (hemoglo-
bin < 10.5 g/dL), severe heart (such as heart failure or with
pacemaker) or liver disease (such as nonmetabolic cirrhosis or
liver failure), medical histories of galactosemia, kidney
transplant, gastrointestinal surgery, drug allergy or sensitivityto analogous drugs, and on any medication that might inter-
fere with drug absorption or metabolism.
This pharmacokinetic studywas conducted by a single dose
and open-labeled design with 6.5-g lactulose in hemodialysis
patients. Prior to dosing, patients were hospitalized and fasted
overnight forat least10hours.Thestudydrugwasadministered
orally with 50mL of room temperature water. The oral cavities
of the patients were inspected after administration to ensure
they swallowed the jelly. Hemodialysis would be performed
afterdosing for 24hours.All patientswereservedwith thesame
standardized meals provided by study site staff during the
hospitalization. No other food was allowed until 5 hours after
administration. Water was available upon request. Alcohol,
coffee, tea, cocoa, or cola were forbidden before 48 hours.
2.3. Pharmacokinetic measurement and analysis
Blood samples were obtained from the patient's forearm cuta-
neous vein into evacuated tubes containing sodium heparin
prior to dosing and 1 hour, 2 hours, 3 hours, 4 hours, 5 hours,
6 hours, 7 hours, 8 hours, 10 hours, 12 hours, and 24 hours after
dosing as well as the next day at the end of dialysis (28 hours
after dosing) and stored in ice. Within 1 hour, plasma was
separatedby centrifugation at 1900 g for 10minutes at 4C.After
that, plasma specimens were stored frozen at 80C before
further liquid chromatography-tandem mass spectrometry
analysis for lactulose concentration. Vital signs including blood
pressure,heart rate, andbodytemperaturewere recordedonthe
day before dosing, just prior to dosing and 24-hours postdosing.
WinNonlin 6.3 (Pharsight Corporation, Saint Louis, MO,
USA) was used to analyze pharmacokinetic parameters (Cmax,
Tmax, AUC0e24h, and AUC0e28h) based on lactulose plasma
concentration of each time point using noncompartmental
models. The peak plasma concentration (Cmax) and time to
reach Cmax (Tmax) were individually measured. Meanwhile, the
plasma concentrationearea under the concentrationetime
curves (AUC0e24h and AUC0e28h) were calculated from
measured values using the trapezoidal method. The removal
rate (%) of drugs by dialysis was calculated using the plasma
concentration before (24 hours after administration) and after
dialysis (28 hours after administration) and Eq. (1). For simu-
lation of repeated administrations, method of residuals was
applied and calculated based on pharmacokinetic parameters
to simulate the variations of plasma concentrations.
Rate of drug removal (%) ¼ [(concentration before
dialysis e concentration after dialysis)/concentration before
dialysis]  100 (1)
3. Results
3.1. Pharmacokinetics
The transition of the plasma concentration at each time point
after lactulose administration, calculated pharmacokinetic pa-
rameters, and removal rate of drugs by dialysis are shown in
Table 1. The mean plasma concentration 24 hours after
administration was 2220 ± 986 ng/mL. A decreased concentra-
tion of 307 ± 117 ng/mL was found after dialysis. Cmax was
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56,200 ± 21,300 ng h/mL. AUC0e28h was 61,200 ± 23,300 ng h/mL
including dialysis which was carried out during 24e28 hours.
The rate of lactulose removal by dialysiswas 69.5e93.5% (mean:
83.6 ± 8.9%). In addition, themean plasma concentrationetime
curveof lactulose isshown inFigure1.Themean lactulose levels
were markedly decreased after hemodialysis. Figures 2 and 3
showed the prediction of repeated oral lactulose administra-
tion with different frequenciesdone sachet daily and one
sachet every 12 hours, respectively. The solid line shows the
mean plasma concentrationetime profile when 6.5-g lactulose
was administered immediately after the end of dialysis. Based
on the above plasma concentrationetime profile shown in
Figure 1, the dotted lines in Figures 2 and 3 show the plasma
concentrationetime profile.Figure 1 e The mean plasma concentrationetime profile of
lactulose. The arrows marked with “HD” indicate the
hemodialysis start (24 hours) and end (28 hours).3.2. The assessment of safety and tolerability
The adverse event of mild diarrhea was reported in one of six
cases during the study. Considering the pharmacological ef-
fects of lactulose, there is a high possibility that diarrhea
occurred after administration. Except for the former mention,
no adverse events occurred during the study. With regard to
clinical testing, no particular changes were observed during
screening or follow-up inspection. Neither of vital signs nor
electrocardiograms showed significant changes. Overall, lac-
tulose was well tolerated in the present study when a single
dose of lactulose was administered to hemodialysis patients.4. Discussion
Chronic kidney disease is a global public health problem and
the prevalence of end-stage renal disease is persistentlyTable 1 e Plasma concentrations and pharmacokinetic parame
hemodialysis patients.
Time after administration (h)
No. 1 No. 2 No.
Pre 0 0 0
1 462 502 201
2 888 1260 990
3 1000 3140 1050
4 1690 3840 1180
5 1490 3410 1840
6 1570 3690 2450
7 2240 3220 2630
8 2590 2750 2460
10 1730 3310 2240
12 2050 3290 2440
24a 1240 2850 1690
28b 247 374 516
Cmax (ng/mL) 2590 3840 2630
Tmax (h) 8.0 4.0 7.0
AUC0e24h (ng$h/mL) 38,475 69,937 45,73
AUC0e28h (ng$h/mL) 41,449 76,385 50,14
R.r. (%) 80.1 86.9 69.5
AUC ¼ area under the curve; Cmax ¼maximum plasma concentration; R.r
a Hemodialysis start.
b Hemodialysis end.increasing [11]. The use of lactulose is not uncommon in he-
modialysis patients [12]. In this study, we demonstrated the
pharmacokinetic transition of lactulose concentration in pa-
tients with maintenance hemodialysis.
In an earlier study reported by Hinohara and Suzuki [9], a
maximum plasma concentration of 56.8 ± 25.2 mg/mL was
observed after five healthy adults orally received 19.5 g lac-
tulose syrup for 4 hours. However, a similar study design
applied in Takimoto et al's [13] research showed a maximum
plasma concentration of 10.7 ± 15.2 mg/mL. In comparison
with the aforementioned results, the slight absorption of
lactulose was observed corresponding to the dosage which
had been given. Also, considering that the incomparable
values of Cmax may be attributed to individual differences, itters of lactulose (6.5 g) after oral administration in
Concentration (ng/mL)
3 No. 4 No. 5 No. 6 Mean SD
0 0 24.7 4.12 10.08
673 882 766 581 244
1790 2150 962 1340 517
2380 2730 1030 1890 974
3260 3940 1170 2510 1312
3500 3860 1200 2550 1167
3560 3460 1580 2720 989
3620 3760 1560 2840 853
3470 3840 1400 2750 853
3940 3850 1370 2740 1109
3490 3630 1220 2690 950
2990 3430 1140 2220 986
256 222 225 307 117
3940 3940 1580 3087 975
10.0 4.0 6.0 6.50 2.35
1 74,238 80,232 28,500 56,186 21,300
3 80,730 87,536 31,230 61,246 23,307
91.4 93.5 80.3 83.6 8.9
. ¼ removal rate; SD ¼ standard deviation; Tmax. ¼ time to reach Cmax.
Figure 2 e Prediction of repeated oral lactulose
administration (one sachet daily). The solid line shows the
mean plasma concentrationetime profile when lactulose
6.5 g was administered immediately after the end of
dialysis. Based on the plasma concentrationetime profile
shown in Figure 1, the dotted line shows the plasma
concentrationetime profile (dialysis is performed 72 hours
after the 1st administration) by administration in 24-hour
intervals for 3 consecutive days. The arrows marked with
“HD” indicate when hemodialysis was carried out.
Figure 3 e Prediction of repeated oral lactulose
administration (one sachet every 12 hours). The solid line
shows the mean plasma concentrationetime profile when
lactulose 6.5 g was administered immediately after the end
of dialysis. Based on the plasma concentrationetime
profile shown in Figure 1, the dotted line shows the plasma
concentrationetime profile after repeated administrations
in 12-hour intervals. Dialysis is performed after 3 days,
then 2 days later, then 2 days later (3 times/wk;
administration performed immediately after dialysis). The
arrows marked with “HD” indicate when hemodialysis
was carried out.
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concentration. Furthermore, another report revealed that the
plasma concentration of lactulose was only detectable in oneof the two cases who received the highest dosage of 53 g
(maximum plasma concentration of 12.1 mg/mL will be ex-
pected when dosage converted to 19.5 g) [14]. Based on the
data obtained from the present study, the results showed that
the plasma level of lactulose was low, and comparable to
healthy adults. It is expected that themeanmaximumplasma
concentration will be 9.27 mg/mL if a single dose of lactulose
19.5 g is administered to dialysis patients. Taken together, our
observations confirmed that a slight amount of lactulose was
absorbed in dialysis patients, whichwas also comparablewith
previous findings.
Absorbed lactulose is not metabolized in the human body
and is excreted as a parental form in urine [1]. A previous
study indicated that unchanged lactulose in urinary excre-
tion has been determined to be 0.65% of the administrated
lactulose after a healthy adult received lactulose orally for
12 hours [9]. Out of the six cases with lactulose treatments,
only one excreted 2.8% of the parental drug into urine, while
the others had an unchanged excretion of <1% of the dosage
[14]. It also confirmed the observation associated with mar-
ginal lactulose absorption in terms of the small amount of
urinal excretion. In contrast to healthy adults whose absor-
bed lactulose was remove through excretion into urine, the
plasma concentration of lactulose remained unchanged in
dialysis patients due to their inability to excrete urine.
Furthermore, an issue that needs to be addressed is that
repeated dosing may cause elevated plasma levels of
lactulose.
Based on pharmacokinetic parameters and dialysis
removal rate obtained from this study, method of residuals
was applied to simulate the plasma concentration of dialysis
patients who were administered repeatedly. Two simulations
were made. In the first simulation, lactulose 6.5 g was
administered once a day in 24-hour intervals, while dialysis
was carried out once every 72 hours (administration is done
before dialysis; Simulation 1; Figure 2). In the second simula-
tion, a dose of lactulose 6.5 g was administered in 12-hour
intervals (dialysis was 3 times/wk in intervals of 3 days,
2 days, and 2 days; Simulation 2; Figure 3). In Simulation 1,
after the first administration for 54 hours, the maximum
plasma concentration was near 6000 ng/mL, but did not in-
crease thereafter, and showed a tendency to decrease even
with continued administration. In the sameway, Simulation 2
using the 3-day interval, the maximum plasma concentration
reached about 11,000 ng/mL before dialysis (64 hours after the
first administration), then showed a downward trend. Based
on our finding, it is unlikely that the plasma concentrationwill
increase by repeated administration. The maximum plasma
concentration is estimated to be about 6000 ng/mL when
administered once a day, and about 11,000 ng/mL when
administered twice a day.
In conclusion, the present study is the first to demonstrate
the pharmacokinetics, removal rate of hemodialysis, and
safety of lactulose in Taiwanese patients with CRF, even
though the small sample size may affect the clinical repre-
sentative. Certainly, multiple-dose administration will be
conducted to investigate the long-term pharmacokinetics
profile of lactulose in hemodialysis patients and the fidelity of
simulation for repeated doses will be addressed.
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